IBTA e-News February 2019 now out

By 28th February 2019 March 30th, 2019 News archive
[28 February 2019] The IBTA's monthly e-News has been released and has emailed to all subscribers. To sign up to receive your copy, click here.

You can also read the IBTA e-News February 2019 edition in full online here.

Some of the highlights from this month's round-up:

  • A study published in Nature Medicine has shown that the immune checkpoint inhibitor pembrolizumab (Keytruda) may  be an effective treatment for recurrent glioblastoma when used before surgery, rather than afterwards.
  • A panel of international brain cancer researchers tasked by Cancer Research UK (CRUK)  to identify the most important challenges to be overcome in order to successfully treat patients with brain tumours have summarised their findings in a Position Paper published in Nature Reviews Clinical Oncology.
  • A new device, dubbed the “Tumour Monorail”, that mimics the brain’s white matter to attract brain tumour cells toward the outer surfaces of the brain has been granted ‘breakthrough device’ status by the US Food and Drug Administration (FDA).
  • The European Organization for Research and Treatment of Cancer (EORTC) has developed a project to perform molecular analysis of tumour samples from young adult patients (12 to 29 years old) with rare cancers, including glioma.
  • A retrospective analysis of 156 glioblastoma patients comparing the effects of standard radiation dose (60 Gray [Gy]) with a moderate dose-escalation regimen (up to 66 Gy) found that dose-escalation therapy correlated with an improved time to relapse and overall survival.
  • Christine Mungoshi, Director of the Zimbabwe Brain Tumour Association (ZBTA), has been appointed as an IBTA Senior Advisor for patient advocacy in Sub-Saharan Africa.
  • March marks Brain Tumour Awareness Month in the UK - a time when charities, groups and individuals across the country take the opportunity to fundraise and highlight to the general public the importance of improved brain tumour research, treatment and support.

Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 6,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.

To see an archive of existing e-News issues, click here.